<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00125996</url>
  </required_header>
  <id_info>
    <org_study_id>FERRIC-HF</org_study_id>
    <secondary_id>FERRIC-Hef1</secondary_id>
    <secondary_id>RD010</secondary_id>
    <secondary_id>131/03L</secondary_id>
    <nct_id>NCT00125996</nct_id>
  </id_info>
  <brief_title>Effect of Intravenous Ferrous Sucrose on Exercise Capacity in Chronic Heart Failure</brief_title>
  <official_title>A Randomised Controlled Study to Assess the Acute and Chronic Effects of Intravenous Iron Supplementation in Anaemic and Non-Anaemic Iron Deficient Patients With Chronic Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Heart and Lung Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Wexham Park Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>4th Military Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Heart and Lung Institute</source>
  <brief_summary>
    <textblock>
      This is a two-center, randomised, single-blind (physician), prospective, controlled study to&#xD;
      assess the acute (8 weeks) and chronic (16 weeks) effects of intravenous (IV) iron sucrose&#xD;
      supplementation in anaemic and non-anaemic iron deficient patients with chronic heart failure&#xD;
      (CHF).&#xD;
&#xD;
      The hypotheses are:&#xD;
&#xD;
        -  Treatment of anaemic and non-anaemic iron-deficient CHF patients with IV iron sucrose&#xD;
           improves exercise capacity as measured by peak VO2.&#xD;
&#xD;
        -  IV iron sucrose is safe and well tolerated in subjects with moderate to severe CHF.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Phase and Design:&#xD;
&#xD;
      Prospective two-centre, randomized, controlled, open-label, observer-blinded, parallel-group&#xD;
      study&#xD;
&#xD;
      Primary Objective:&#xD;
&#xD;
      To evaluate the effect of intravenous (IV) iron supplementation on exercise tolerance, as&#xD;
      determined by peak VO2.&#xD;
&#xD;
      Secondary Objectives:&#xD;
&#xD;
        -  To evaluate the effects of IV iron supplementation on exercise duration, left&#xD;
           ventricular (LV) structure and function, symptom status (NYHA class, Minnesota Living&#xD;
           with Heart Failure Questionnaire [MLHFQ], and subjective fatigue score), and&#xD;
           haematological and biochemical (haemoglobin [Hb], haematocrit [Hct], iron status, N-BNP,&#xD;
           cytokines and oxidative stress) indices.&#xD;
&#xD;
        -  To evaluate the safety profile of IV iron in subjects with moderate to severe CHF.&#xD;
&#xD;
      Sample Size:&#xD;
&#xD;
      42 subjects (28 IV iron, 14 placebo); 50% anaemic and 50% non-anaemic&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2004</start_date>
  <completion_date>February 2006</completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in peak VO2 from baseline to week 18</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in cardiopulmonary exercise duration from baseline to week 18</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in distance walked during 6 minute walk test from baseline to end of repletion phase in treatment group or week 8 in control group, and week 18</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in left ventricular (LV) systolic and diastolic dimensions, and function from baseline to week 18</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in symptom status (New York Heart Association [NYHA] class, Minnesota Living with Heart Failure Questionnaire [MLHFQ], visual analogue fatigue scale) from baseline to week 1,week 8, and week 18</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in haematological and biochemical indices (Hb, Hct, iron status, N-BNP, cytokines and oxidative stress) from baseline to week 18</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and incidence of adverse events</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in liver function tests and renal function tests</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in vital parameters</measure>
  </secondary_outcome>
  <enrollment>42</enrollment>
  <condition>Chronic Heart Failure</condition>
  <condition>Heart Diseases</condition>
  <condition>Anemia, Iron-Deficiency</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Venofer (intravenous iron sucrose)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ≥21 years of age and have signed written informed consent&#xD;
&#xD;
          -  Stable symptomatic CHF; NYHA III/IV and left ventricular ejection fraction (LVEF)&#xD;
             ≤40%, or if NYHA II then LVEF must be ≤35%, as assessed within last 6 months using&#xD;
             echocardiographic or magnetic resonance imaging techniques.&#xD;
&#xD;
          -  On optimal conventional therapy for at least 4 weeks prior to recruitment and without&#xD;
             dose changes for at least 2 weeks.&#xD;
&#xD;
          -  Peak VO2 ≤ 18 ml/kg/min on modified Naughton protocol cardiopulmonary exercise&#xD;
             testing.&#xD;
&#xD;
          -  Mean of the 2 screening Hb concentrations (week-2 and week-1) &lt; 12.5 g/dl (anaemic&#xD;
             group, 50% of study population) or 12.5-14.0 g/dl (non-anaemic group, 50% of study&#xD;
             population).&#xD;
&#xD;
          -  Ferritin &lt;100 µg/l or 100-300 µg/l with TSAT &lt;20%.&#xD;
&#xD;
          -  Normal red cell folate and vitamin B12 status (according to local lab reference&#xD;
             range).&#xD;
&#xD;
          -  Resting blood pressure ≤160/100 mmHg.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of acquired iron overload; known haemochromatosis or first relatives with&#xD;
             haemochromatosis; and allergic disorders (asthma, eczema, and anaphylactic reactions).&#xD;
&#xD;
          -  Known hypersensitivity to parental iron preparations.&#xD;
&#xD;
          -  Known active infection, bleeding, malignancy and haemolytic anaemia.&#xD;
&#xD;
          -  History of chronic liver disease and/or alanine transaminase (ALT) or aspartate&#xD;
             transaminase (AST) &gt;3 times the upper limit of the normal range; chronic lung disease;&#xD;
             myelodysplastic disorder; and known HIV/AIDS disease.&#xD;
&#xD;
          -  Recipient of immunosuppressive therapy or renal dialysis.&#xD;
&#xD;
          -  History of erythropoietin, IV or oral iron therapy, and blood transfusion in previous&#xD;
             30 days.&#xD;
&#xD;
          -  Unstable angina pectoris, as judged by the investigator; severe uncorrected valvular&#xD;
             disease or left ventricular outflow obstruction; obstructive cardiomyopathy;&#xD;
             uncontrolled fast atrial fibrillation or flutter (heart rate &gt;110 beats per minute&#xD;
             [bpm]); uncontrolled symptomatic brady- or tachyarrhythmias.&#xD;
&#xD;
          -  Musculoskeletal limitation that, in the judgement of the investigator, would impair&#xD;
             cardiopulmonary exercise testing.&#xD;
&#xD;
          -  Pregnant or breast-feeding&#xD;
&#xD;
          -  Inability to comprehend study protocol&#xD;
&#xD;
          -  Parallel participation in another clinical trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>95 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philip A Poole-Wilson, MD,FRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>NHLI, Imperial College School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Darlington O Okonko, BSc, MRCP</last_name>
    <phone>02073518700</phone>
    <email>D.OKONKO@IC.AC.UK</email>
  </overall_contact>
  <location>
    <facility>
      <name>4th Military Clinical Hospital</name>
      <address>
        <city>Weigla 5</city>
        <state>Wroclaw</state>
        <zip>50981</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Piotr Ponikowski, MD PHD</last_name>
      <phone>(48) 717660250</phone>
      <email>piotrponikowski@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Piotr Ponikowski, MD PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wexham Park Hospital</name>
      <address>
        <city>Wexham Park, Slough</city>
        <state>Berkshire</state>
        <zip>SL2 4HL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Constantinous Missouris, MD</last_name>
      <phone>(44)01753 634680</phone>
      <email>cmissouris@btopenworld.com</email>
    </contact>
    <contact_backup>
      <last_name>Amit K Mandall, MRCP</last_name>
      <phone>(44)01753 634680</phone>
      <email>akjm@mac.com</email>
    </contact_backup>
    <investigator>
      <last_name>Constantinous Missouris, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Poland</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>January 2005</verification_date>
  <study_first_submitted>August 1, 2005</study_first_submitted>
  <study_first_submitted_qc>August 1, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 2, 2005</study_first_posted>
  <last_update_submitted>August 16, 2005</last_update_submitted>
  <last_update_submitted_qc>August 16, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 17, 2005</last_update_posted>
  <keyword>ANAEMIA</keyword>
  <keyword>Iron Deficiency</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Anemia, Iron-Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ferric Oxide, Saccharated</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

